Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis.
Odd L GammelgaardMikkel G TerpAlexei F KirkinSimone JohansenSofie TraynorHenriette VeverPer GuldbergAnnette Raskov KodahlMorten Frier GjerstorffHenrik Jørn DitzelPublished in: Molecular cancer (2024)
Combined ALECSAT and anti-PDL1 therapy results in favorable anti-cancer responses in both cell line-derived xenograft and autologous PDX models of advanced triple-negative breast cancer.